2016 American Transplant Congress
Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using ASTAGRAF XL® Despite a Higher Degree of HLA Mismatch : A Post-Hoc Analysis of Phase III Data from Over 2000 Patients.
Astelleas Pharma Global Develepment, Northbrook, IL.
INTRO: When contemplating the use of a new immunosuppressant agent in kidney transplantation, measuring outcomes in potentially vulnerable populations is of paramount concern. As such,…2016 American Transplant Congress
Does Post-Transplant Adherence Come at a Cost?
University of Minnesota, Minneapolis, MN.
Background: It is well documented that organ transplant (tx)recipients have an increased incidence of cancer including virus associated cancers like lymphoma. Our objective was to…2016 American Transplant Congress
Mycophenolic Acid Product Discontinuation Prior to Conception: Analysis of Pregnancies in Kidney Transplant Recipients.
Mycophenolic acid (MPA) products are considered teratogenic and transplant centers report discontinuing MPA in female kidney recipients anticipating pregnancy. Data were collected by the National…2016 American Transplant Congress
Avoidance of CNI and Steroids Using Belatacept – A Preliminary Report of CTOT-16.
1UAB, Birmingham; 2UCSF, San Francisco; 3Emory, Atlanta; 4Rho, Chapel Hill; 5NIAID, Bethesda.
CTOT-16 tested the hypothesis that belatacept used as maintenance immunosuppression (IS) in kidney transplantation would allow the long-term avoidance of CNI and corticosteroids. Methods: Primary…2016 American Transplant Congress
Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with a Moderate Splenic B-Cell Reduction.
Comprehensive Transplantation Center/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Bruton tyrosine kinase (Btk) is specifically required for activation of the B-cell antigen receptor signaling pathway that contributes to the initiation and maintenance of…2016 American Transplant Congress
Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.
Background: Medication non-adherence (MNA) is a significant contributor to late graft loss in kidney transplant recipients. The aim of this study was to develop and…2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…2016 American Transplant Congress
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
Cardiology, University of California-Los Angeles, Los Angeles, CA.
Purpose: The presence of circulating HLA antibodies which is termed allosensitization among heart transplant (HTx) candidates are associated with poorer posttransplant outcomes including increased morbidity…2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression.
Human bone marrow derived MSC-17 are superior T cell immunomodulators for allotransplantation. Untreated-MSC (UT-MSC) or 5 days IFNγ (MSCγ) or IL-17A (MSC-17) treated MSC were…
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 138
- Next Page »